Binds Antigen Characterized By Name Or Molecular Weight (e.g., Cea, Nca, Cc Glycoprotein, Melanoma Gp 150 Antigen, Etc.) Patents (Class 530/388.85)
-
Patent number: 6991776Abstract: New intracorporeal radiodense medicaments and certain medical uses and methods for use of such high energy phototherapeutic medicaments for treatment of human or animal tissue are described, wherein a primary active component of such medicaments is a halogenated xanthene or halogenated xanthene derivative. The halogenated xanthenes constitute a family of potent radiosensitizers that become photoactivated upon irradiation of the treatment site with ionizing radiation.Type: GrantFiled: December 30, 2002Date of Patent: January 31, 2006Assignee: Xantech Pharmaceuticals, Inc.Inventors: H. Craig Dees, Timothy C. Scott, Eric A. Wachter, Walter G. Fisher, John Smolik
-
Patent number: 6986891Abstract: The present invention is directed to cell surface antigens found on myeloma cells and on ovarian cancer cells, and monoclonal antibodies, and antibody binding fragments thereof, capable of being used for therapeutic, diagnostic, detection and cell purification purposes. An exemplified monoclonal antibody of the present invention recognizes and binds to an epitope common to surface antigen expressed on multiple myeloma cells and on ovarian cancer cells.Type: GrantFiled: November 28, 2001Date of Patent: January 17, 2006Assignee: Molecular Discoveries, L.L.C.Inventor: Cohava Gelber
-
Patent number: 6972324Abstract: The present invention belongs to the field of oncology. The invention relates to antibodies with specified sequence which are specific for an epitope which is coded by the variant exon v6 of the CD44 gene and to derivatives of said antibody. The invention also provides nucleic acid molecules encoding said antibody proteins. The invention furthermore pertains to methods for producing said antibody proteins. The invention also provides pharmaceutical compositions comprising said antibody proteins. The invention furthermore is concerned with the use in the manufacture of a medicament for the treatment of cancer.Type: GrantFiled: May 20, 2002Date of Patent: December 6, 2005Assignees: Boehringer Ingelheim Pharmaceuticals, Inc., Boehringer Ingelheim International, GmbHInventors: Günther Adolf, Elinborg Ostermann, Erik Patzelt, Marlies Sproll, Karl-Heinz Heider, John J. Miglietta, Augustinus Antonius Maria Silvester Van Dongen
-
Patent number: 6965024Abstract: A humanized chimera antibody, a pharmaceutical composition comprising a humanized chimera antibody and a pharmaceutically acceptable carrier, and a method of treating cancer which comprises administering to a patient a pharmaceutically acceptable amount of said humanized chimera antibody, are disclosed.Type: GrantFiled: October 8, 2002Date of Patent: November 15, 2005Assignee: Kyowa Hakko Kogyo Co., Ltd.Inventors: Kenya Shitara, Nobuo Hanai, Mamoru Hasegawa, Hiromasa Miyaji, Yoshihisa Kuwana
-
Patent number: 6965016Abstract: A 22 kD sperm protein, SP22, correlates with fertility and predicts fertility in males. The protein can be assayed to detect decreases in fertility resulting from exposure to toxicants and pollutants which are known or suspected to decrease fertility. In an antibody is generated to this protein, the antibody recognition by sperm in an epididymal sperm sample or ejaculate would reflect the fertility of the sample. This antibody can be used as a contraceptive to inactivate sperm, screen for toxicity, select animals for artificial insemination, and select men for assisted reproductive technologies. The protein itself can be inactivated by gene knockout, which is another approach to contraception, or the protein can be added to sperm from infertile men to make fertility techniques more feasible.Type: GrantFiled: January 3, 2001Date of Patent: November 15, 2005Assignee: The United States of America as represented by the U.S. Environmental Protection AgencyInventor: Gary Klinefelter
-
Patent number: 6965017Abstract: The present invention provides a nucleic acid sequence encoding a melanoma antigen recognized by T lymphocytes, designated MART-1. This invention further relates to bioassays using the nucleic acid sequence, protein or antibodies of this invention to diagnose, assess or prognoses a mammal afflicted with melanoma or metastata melanoma. This invention also provides immunogenic peptides derived from the MART-1 melanoma antigen and a second melanoma antigen designated gp100. This invention further provides immunogenic peptides derived from the MART-1 melanoma antigen or gp100 antigen which have been modified to enhance their immunogenicity. The proteins and peptides provided can serve as an immunogen or vaccine to prevent or treat melanoma.Type: GrantFiled: July 3, 2001Date of Patent: November 15, 2005Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Yutaka Kawakami, Steven A. Rosenberg
-
Patent number: 6962779Abstract: The present invention provides a new method for detecting, diagnosing, monitoring, staging, prognosticating, imaging and treating gastointestinal cancers including small intestine, colon and stomach cancer.Type: GrantFiled: September 30, 1999Date of Patent: November 8, 2005Assignee: diaDexus, Inc.Inventor: Roberto A. Macina
-
Patent number: 6960443Abstract: The invention provides a novel prostate cell-surface antigen, designated Prostate Stem Cell Antigen (PSCA), which is widely over-expressed across all stages of prostate cancer, including high grade prostatic intraepithelial neoplasia (PIN), androgen-dependent and androgen-independent prostate tumors.Type: GrantFiled: August 20, 2002Date of Patent: November 1, 2005Assignee: The Regents of the University of CaliforniaInventors: Robert E. Reiter, Owen N. Witte
-
Patent number: 6955717Abstract: The present invention provides machine readable media embedded with the three-dimensional atomic structure coordinates of Synagis Fab, and subsets thereof, and methods of using them.Type: GrantFiled: April 29, 2002Date of Patent: October 18, 2005Assignees: Medimmune Inc., Bowie State UniversityInventors: Leslie S. Johnson, Bradford Braden
-
Patent number: 6951926Abstract: Nuclear matrix proteins (NMP) which are characterized by a defined expression in tissue are provided. These NMPs are useful markers in diagnosing and monitoring the stage of malignancy of a cell and treating cell proliferative disorders associated with the NMP. Also provided are substantially purified polypeptides and nucleotide sequences encoding the NMPs of the invention.Type: GrantFiled: May 30, 2001Date of Patent: October 4, 2005Assignee: University of PittsburghInventor: Robert H. Getzenberg
-
Patent number: 6946129Abstract: The present invention relates to methods and compositions for the prevention and treatment of cancer, inflammatory diseases and disorders or deficiencies of the immune system. The methods of the invention comprise administering a CD40 binding protein that potentiates the binding of CD40 to CD40 ligand.Type: GrantFiled: June 8, 1999Date of Patent: September 20, 2005Assignee: Seattle Genetics, Inc.Inventors: Clay B. Siegall, Alan F. Wahl, Joseph A. Francisco, Henry Perry Fell, Jr.
-
Patent number: 6933368Abstract: The present invention provides methods for producing mutationally-altered immunoglobulins and compositions containing such mutationally-altered immunoglobulins, wherein the mutationally-altered immunoglobulins have at least one mutation that alters the pattern of glycosylation in a variable region and thereby modifies the affinity of the immunoglobulin for a preselected antigen. The methods and compositions of the invention provide immunoglobulins that possess increased affinity for antigen. Such glycosylation-altered immunoglobulins are suitable for diagnostic and therapeutic applications.Type: GrantFiled: February 25, 2002Date of Patent: August 23, 2005Assignees: Protein Design Labs, Inc., Memorial Sloan Kettering Cancer CenterInventors: Man Sung Co, David A. Scheinberg, Cary L. Queen
-
Patent number: 6924360Abstract: The present invention relates generally to the generation and characterization of anti-MUC18 monoclonal antibodies. The invention further relates to the use of such anti-MUC18 antibodies in the diagnosis and treatment of disorders associated with increased activity of MUC18, in particular, tumors, such as melanomas.Type: GrantFiled: December 26, 2002Date of Patent: August 2, 2005Assignee: Abgenix, Inc.Inventors: Larry L. Green, Menashe Bar-Eli
-
Patent number: 6896885Abstract: The present invention discloses combined therapies for treating hematologic malignancies, including B cell lymphomas and leukemias or solid non-hematologic tumors, comprising administration of anti-cytokine antibodies or antagonists to inhibit the activity of cytokines which play a role in perpetuating the activation of B cells. The administration of such antibodies and antagonists, particularly anti-IL10 antibodies and antagonists, is particularly useful for avoiding or decreasing the resistance of hematologic malignant cells or solid tumor cells to chemotherapeutic agents and anti-CD20 or anti-CD22 antibodies. The invention also provides combination therapies for solid tumors having B cell involvement comprising the administration of an anti-cytokine antibody and a B cell depleting antibody such as RITUXAN® (rituximab).Type: GrantFiled: April 2, 2001Date of Patent: May 24, 2005Assignee: Biogen Idec Inc.Inventor: Nabil Hanna
-
Patent number: 6897044Abstract: The present invention relates to a novel process for the preparation of biologically active antibody dimers in a pharmaceutically acceptable composition. The dimers can be composed of two antibody molecules having the same antigen binding specificity and linked through reducible, disulfide, or a non-reducible thioether, bond (homodimer). Alternatively, the dimers can be composed of two different antibody molecules having binding specificity for two distinct antigens (heterodimer). These dimers are useful for inducing hyper-cross-linking of membrane antigens. The present invention further relates to the use of biologically active antibody dimers for the preferential killing or inhibition of selected cell populations in the treatment of diseases such as cancer and autoimmune disorders.Type: GrantFiled: January 28, 1999Date of Patent: May 24, 2005Assignee: Biogen Idec, Inc.Inventors: Gary R Braslawsky, Nabil Hanna, Kandasamy Hariharan, Michael J LaBarre, Tri B Huynh
-
Patent number: 6894149Abstract: This invention provides anti-HLA-DR antibodies and the methods of use thereof for the treatment of leukemia or lymphomas, or solid tumors such as ovarian cancer or melanoma.Type: GrantFiled: October 10, 2002Date of Patent: May 17, 2005Assignee: Protein Design Labs, Inc.Inventors: J. Yun Tso, Jennifer McPhate Green
-
Patent number: 6891023Abstract: Novel recombinant antibodies from murine antibody IOR C5 produced by the hybridoma deposited with the ECCC 97061101. The recombinant antibodies were obtained using recombinant DNA technology and are characterized in that they recognize antigen ior C2. The recombinant antibodies are specifically chimeric antibody, humanized antibody, and single chain Fv fragment. The chimeric antibody contains the variable domains of the murine immunoglobuline and the constant regions of the human immunoglobuline. The humanized antibody contains the constant regions of human immunoglobuline and has been specifically modified in the murine frameworks regions (FRs) and within the latter, in those areas that may result in an antigenic site for cells T. The Fv fragment contains the variable domains of murine immunoglobuline. The invention also relates to the utilization of recombinant antibodies derived from murine antibody ior C5 in the diagnosis and therapy of colorectal tumors, the metastasis thereof and recurrences.Type: GrantFiled: November 16, 2000Date of Patent: May 10, 2005Assignee: Centro Inmunologia MolecularInventors: Cristina Maria Mateo de Acosta Del Rio, Lourdes Tatiana Roque Navarro, Alejo Morales Morales, Rolando Pérez Rodríguez, Marta Ayala Ávila, Jorge Victor Gavilondo Cowley, Marta Dueñas Porto, Hanssel Bell García, Enrique Rengifo Calzado, Normando Iznaga Escobar, Mayra Ramos Zuzarte
-
Patent number: 6891022Abstract: The present invention relates to nucleotide sequences, including expressed sequence tags (ESTs), oligonucleotide probes, polypeptides, antagonists and agonists vectors and host cells expressing, and immunoadhesions and antibodies to PRO201, PRO308 or PRO309 polypeptides. The invention further relates to compositions and method for the diagnosis and treatment of neoplastic cell growth and proliferation in mammals, including humans. The invention is based in part on the identification of genes that are amplified in the genome of tumor cells. Such gene amplification is expected to be associated with the overexpression of the gene product and contribute to tumorigenesis. Accordingly, the proteins encoded by the amplified genes are believed to be useful targents for the diagnosis and/or treatment (including prevention) of certain tumors (e.g., cancer) and may act as predictors of the prognosis of tumor treatment.Type: GrantFiled: April 23, 1999Date of Patent: May 10, 2005Assignee: Genentech, Inc.Inventors: Timothy A. Stewart, Yanmei Lu
-
Patent number: 6890724Abstract: The invention relates to methods and compositions for the isolation of neural progenitor cells.Type: GrantFiled: September 25, 1996Date of Patent: May 10, 2005Assignee: California Institute of TechnologyInventors: David J. Anderson, Li-Ching Lo
-
Patent number: 6887983Abstract: The present invention relates, in general, to presenilin 2 proteolytic fragments. In particular, the present invention relates to a purified 20 kDa presenilin 2 C-terminal fragment (PS2-CTF); purified nucleic acid molecules coding for the 20 kDa PS2-CTF protein; cells containing the nucleic acid molecules; non-human organisms containing the nucleic acid molecule; antibodies having specific binding affinity to the 20 kDa PS2-CTF; hybridomas containing the antibodies; methods of detecting 20 kDa PS2-CTF in a sample; diagnostic kits; methods for screening compounds that inhibit proteolytic processing of presenilin 2 in a cell, isolated compounds that inhibit proteolytic processing of presenilin 2 in a cell, and a method of inhibiting apoptotic cell death by preventing proteolytic cleavage of presenilin 2 at a cleavage site which generates a 20 kDa C-terminal fragment.Type: GrantFiled: April 24, 1998Date of Patent: May 3, 2005Assignee: The General Hospital CorporationInventors: Rudolph E. Tanzi, Tae-Wan Kim
-
Patent number: 6884879Abstract: Humanized and variant anti-VEGF antibodies and various uses therefor are disclosed. The anti-VEGF antibodies have strong binding affinities for VEGF; inhibit VEGF-induced proliferation of endothelial cells in vitro; and inhibit tumor growth in vivo.Type: GrantFiled: August 6, 1997Date of Patent: April 26, 2005Assignee: Genentech, Inc.Inventors: Manuel Baca, James A. Wells
-
Patent number: 6875432Abstract: The present application concerns concentrated protein formulations with reduced viscosity, which are particularly suitable for subcutaneous administration. The application further concerns a method for reducing the viscosity of concentrated protein formulations.Type: GrantFiled: October 4, 2001Date of Patent: April 5, 2005Assignees: Genentech, Inc., Novartis AGInventors: Jun Liu, Steven J. Shire
-
Patent number: 6870033Abstract: Humanized anti-IL-8 monoclonal antibodies and variants thereof are described for use in diagnostic applications and in the treatment of inflammatory disorders. Also described is a conjugate formed by an antibody fragment covalently attached to a non-proteinaceous polymer, wherein the apparent size of the conjugate is at least about 500 kD. The conjugate exhibits substantially improved half-life, mean residence time, and/or clearance rate in circulation as compared to the underivatized parental antibody fragment.Type: GrantFiled: February 20, 1998Date of Patent: March 22, 2005Assignee: Genentech, Inc.Inventors: Vanessa Hsei, Iphigenia Koumenis, Steven R. Leong, Leonard G. Presta, Zahra Shahrokh, Gerarado A. Zapata
-
Patent number: 6861511Abstract: This invention relates to a substantially purified p100 which is a human neu related protein having a molecular weight in the range from about 97,000 daltons to about 115,000 daltons which corresponds substantially to the extracellular domain of the human neu gene product, said protein being detectable in a biological fluid. In another embodiment this invention relates to assays for detecting this protein. Finally, this invention also concerns monoclonal antibodies which are capable of binding to p100.Type: GrantFiled: June 7, 1995Date of Patent: March 1, 2005Assignee: Bayer CorporationInventors: Walter Patrick Carney, Paula Jean Marks, Gail Patricia Mazzara, Sara Jane McKenzie, Jonathan Hart Morgan, Debra Ann Petit, Robert Allan Weinberg
-
Patent number: 6852320Abstract: The invention relates to compositions which bind T cell inhibitory receptor molecules and modulate T cell activity, and methods of using such compositions. Such compositions include biliary glycoprotein binding agents. Methods for modulating killer T cell activities, including cytotoxicity and proliferation also are provided.Type: GrantFiled: June 19, 2001Date of Patent: February 8, 2005Assignee: The Brigham & Women's Hospital, Inc.Inventor: Richard S. Blumberg
-
Patent number: 6843989Abstract: The present invention relates to methods and compositions for the prevention and treatment of cancer, inflammatory diseases and disorders or deficiencies of the immune system. The methods of the invention comprise administering a CD40 binding protein that potentiates the binding of CD40 to CD40 ligand.Type: GrantFiled: November 28, 2000Date of Patent: January 18, 2005Assignee: Seattle Genetics, Inc.Inventors: Clay B. Siegall, Alan F. Wahl, Joseph A. Francisco, Henry Perry Fell, Jr.
-
Patent number: 6830752Abstract: The present invention concerns molecules which bind and neutralize the cytokine interferon-gamma. More specifically, the present invention relates to sheep-derived antibodies and engineered antibody constructs, such as humanized single-chain Fv fragments, chimeric antibodies, diabodies, triabodies, tetravalent antibodies, peptabodies and hexabodies which can be used to treat diseases wherein interferon-gamma activity is pathogenic. Examples of such diseases are: septic shock, cachexia, multiple sclerosis and psoriasis.Type: GrantFiled: February 7, 2002Date of Patent: December 14, 2004Assignee: Innogenetics N. V.Inventors: Marie-Ange Buyse, Erwin Sablon
-
Patent number: 6828424Abstract: A human tissue inhibitor of metalloproteinases-4 polypeptide and DNA (RNA) encoding such polypeptide and a procedure for producing such polypeptide by recombinant techniques. Also disclosed are methods for utilizing such polypeptide for the treatment of diseases, including arthritis and cancer. Antagonists against such polypeptides and their use as a therapeutic to resorb scar tissue are also disclosed. Diagnostic assays for detecting levels of human TIMP-4 protein and mutations in human TIMP-4 nucleic acid sequence are also disclosed.Type: GrantFiled: April 5, 2002Date of Patent: December 7, 2004Assignee: Human Genome Sciences, Inc.Inventors: John M. Greene, Craig A. Rosen
-
Patent number: 6824780Abstract: The invention provides antibodies targeted at a tumor antigen prevalent on prostate tumors and methods useful in alleviating cancers expressing the antigen, as well as nucleic acids and cells for expressing the antibodies.Type: GrantFiled: October 27, 2000Date of Patent: November 30, 2004Assignee: Genentech, Inc.Inventors: Brigitte Devaux, Gilbert-Andre Keller, Hartmut Koeppen, Lawrence A. Lasky
-
Patent number: 6825326Abstract: The invention provides a novel prostate cell-surface antigen, designated Prostate Stem Cell Antigen (PSCA), which is widely over-expressed across all stages of prostate cancer, including high grade prostatic intraepithelial neoplasia (PIN), androgen-dependent and androgen-independent prostate tumors.Type: GrantFiled: August 21, 2001Date of Patent: November 30, 2004Assignee: The Regents of the University of CaliforniaInventors: Robert E. Reiter, Owen N. Witte
-
Patent number: 6818749Abstract: The invention is directed towards mouse-human chimeric variants of CC49 monoclonal antibodies with minimal murine content. A first aspect of the invention provides CDR variants of humanized monoclonal antibody (HuCC49) in which less than all six (three heavy chain and three light chain) Complementarity Determining Regions (CDRs) of CC49 are present. A second aspect of the invention provides SDR variants of humanized monoclonal antibody (HuCC49) in which only Specificity Determining Regions (SDRs) of at least one CDR from CC49 are present. The invention is also directed towards biotechnological methods of making the variants and therapeutic methods of using the variants.Type: GrantFiled: April 30, 2001Date of Patent: November 16, 2004Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Syed V. S. Kashmiri, Eduardo A. Padlan, Jeffrey Schlom
-
Patent number: 6809184Abstract: Mesothelin is a differentiation antigen present on the surface of ovarian cancers, mesotheliomas and several other types of human cancers. Because among normal tissues, mesothelin is only present on mesothelial cells, it represents a good target for antibody mediated delivery of cytotoxic agents. The present invention is directed to anti-mesothelin antibodies, including Fv molecules with particularly high affinity for mesothelin, and immunoconjugates employing them. Also described are diagnostic and therapeutic methods using the antibodies. The anti-mesothelin antibodies are well-suited for the diagnosis and treatment of cancers of the ovary, stomach, squamous cells, mesotheliomas and other malignant cells expressing mesothelin.Type: GrantFiled: September 27, 2000Date of Patent: October 26, 2004Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Ira H. Pastan, Partha S. Chowdhury
-
Anti-idiotypic antibody which induces an immune response against a glycosphingolipid and use thereof
Patent number: 6805862Abstract: The present invention provides an anti-idiotypic monoclonal antibody which specifically induces an immune response against a glycosphingolipid. Additionally, this invention provides a method of producing the anti-idiotypic monoclonal antibody. Finally, this invention provides a composition of matter comprising an effective amount of a cytokine and a melanoma ganglio-side-specific antibody attached to a carrier.Type: GrantFiled: June 7, 1995Date of Patent: October 19, 2004Assignee: Sloan-Kattering Institute For Cancer ResearchInventors: Paul B. Chapman, Alan N. Houghton -
Patent number: 6797814Abstract: A method for purifying proteins by Protein A chromatography is described which comprises the steps of: (a) adsorbing the protein to Protein A immobilized on a solid phase comprising silica or glass; (b) removing contaminants bound to the solid phase by washing the solid phase with a hydrophobic electrolyte solvent; and (c) recovering the protein from the solid phase.Type: GrantFiled: September 26, 2001Date of Patent: September 28, 2004Assignee: Genentech, Inc.Inventor: Gregory S. Blank
-
Patent number: 6794150Abstract: The invention is a method of identifying the presence of, and monitoring, a disease state in a mammal which is associated with degradation of connective tissue in the mammal. The method detects and determines whether diagnostically or prognostically significant levels of YKL-40 protein and/or YKL-40 peptide are present in a biological sample. The method can be used, for example, to identify the presence of inflammatory joint disease or degeneration of connective tissue in organs. Serum YKL-40 levels as detected and quantified by the invention method are also suggestive of the prognosis for the length of survival in breast cancer patients following recurrence and/or metastasis of their cancers.Type: GrantFiled: December 18, 1998Date of Patent: September 21, 2004Assignee: The Regents of the University of CaliforniaInventors: Paul A. Price, Julia S. Johansen
-
Patent number: 6790444Abstract: Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-&agr; (TNF&agr;) and are useful in vivo diagnosis and therapy of a number of TNF&agr;-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.Type: GrantFiled: January 8, 2001Date of Patent: September 14, 2004Assignees: New York University Medical Center, Centocor, Inc.Inventors: Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight, Scott Siegel
-
Patent number: 6790939Abstract: The invention provides a novel prostate cell-surface antigen, designated Prostate Stem Cell Antigen (PSCA), which is widely over-expressed across all stages of prostate cancer, including high grade prostatic intraepithelial neoplasia (PIN), androgen-dependent and androgen-independent prostate tumors.Type: GrantFiled: May 14, 2001Date of Patent: September 14, 2004Assignee: The Regents of the University of CaliforniaInventors: Robert E. Reiter, Owen N. Witte, Douglas C. Saffran, Aya Jakobovits
-
Patent number: 6790938Abstract: The invention relates to novel nucleic acid sequences which encode human autoantibodies and antiidiotypic antibodies against blood platelet membrane proteins, to novel amino acid sequences of human antibodies, and to their use for the diagnosis and therapy of diseases.Type: GrantFiled: December 3, 1999Date of Patent: September 14, 2004Assignee: ASAT AG Applied Science & TechnologyInventors: Peter Berchtold, Robert F. A. Escher
-
Patent number: 6787638Abstract: The invention provides tumor-specific human monoclonal antibodies and functional fragments. Also provided are nucleic acids encoding tumor-specific human monoclonal antibodies and functional fragments. A method for reducing neoplastic cell proliferation is also provided. The method consists of administering an effective amount of a tumor-specific human monoclonal antibody or functional fragment. Also provided is a method of detecting a neoplastic cell in a sample. The method consists of contacting a cell with a tumor-specific monoclonal antibody or functional fragment and detecting the specific binding of the human monoclonal antibody or functional fragment to the sample.Type: GrantFiled: December 2, 1998Date of Patent: September 7, 2004Assignee: Applied Molecular Evolution, Inc.Inventors: Jeffry D. Watkins, William D. Huse
-
Patent number: 6767541Abstract: The present invention provides methods for obtaining genetic profiles of cancer cells in order to assess the status of a cancer in an individual. In addition, the present invention provides methods for inhibiting the growth of cancer cells that exhibit certain genetic profiles. These methods identify an important link between HER-2/neu overexpression and loss of growth inhibition by the TGF-&bgr; signaling pathway in cancer cells. Compositions as well as therapeutic and diagnostic methodologies based on this disclosure are provided.Type: GrantFiled: March 20, 2001Date of Patent: July 27, 2004Assignees: The Regents of the University of California, Amgen Inc.Inventors: Dennis J. Slamon, Cindy A. Wilson, Frank J. Calzone
-
Patent number: 6765088Abstract: The presented invention relates to monoclonal antibodies useful in sensitive and specific immunological assays for the identification of prions in various tissues and body fluids, the production of such monoclonal antibodies by means of immunization of PrP0/0 mice by means of a new recombinant fragment of PrP and the use of the antibodies, e.g. for therapeutic and preventive treatments of humans and animals suffering from prion diseases.Type: GrantFiled: August 23, 1999Date of Patent: July 20, 2004Assignee: Universität ZürichInventors: Carsten Korth, Beat Stierli, Peter Stregt, Bruno Oesch, Markus Moser
-
Patent number: 6752990Abstract: Novel humanized monoclonal antibodies, humanized antibody fragments, and derivatives thereof which specifically bind TAG-72 are provided as well as methods for their manufacture. These humanized antibodies are useful in the treatment of cancers which express TAG-72 as well as for diagnostic purposes, e.g., for in vivo imaging of tumors or cancer cells which express TAG-72.Type: GrantFiled: October 31, 2001Date of Patent: June 22, 2004Assignee: The Dow Chemical CompanyInventors: W. H. Kerr Anderson, Philip R. Tempest, Frank J. Carr, William J. Harris, Kathryn Armour
-
Patent number: 6753420Abstract: Novel humanized monoclonal antibodies, humanized antibody fragments, and derivatives thereof which specifically bind TAG-72 are provided as well as methods for their manufacture. These humanized antibodies are useful in the treatment of cancers which express TAG-72 as well as for diagnostic purposes, e.g., for in vivo imaging of tumors or cancer cells which express TAG-72.Type: GrantFiled: October 31, 2001Date of Patent: June 22, 2004Assignee: The Dow Chemical CompanyInventors: W. H. Kerr Anderson, Philip R. Tempest, Frank J. Carr, William J. Harris, Kathryn Armour
-
Patent number: 6753152Abstract: Novel humanized monoclonal antibodies, humanized antibody fragments, and derivatives thereof which specifically bind TAG-72 are provided as well as methods for their manufacture. These humanized antibodies are useful in the treatment of cancers which express TAG-72 as well as for diagnostic purposes, e.g., for in vivo imaging of tumors or cancer cells which express TAG-72.Type: GrantFiled: October 31, 2001Date of Patent: June 22, 2004Assignee: The Dow Chemical CompanyInventors: W. H. Kerr Anderson, Philip R. Tempest, Frank J. Carr, William J. Harris, Kathryn Armour
-
Patent number: 6737060Abstract: Novel humanized monoclonal antibodies, humanized antibody fragments, and derivatives thereof which specifically bind TAG-72 are provided as well as methods for their manufacture. These humanized antibodies are useful in the treatment of cancers which express TAG-72 as well as for diagnostic purposes, e.g., for in vivo imaging of tumors or cancer cells which express TAG-72.Type: GrantFiled: October 31, 2001Date of Patent: May 18, 2004Assignee: The Dow Chemical CompanyInventors: W. H. Kerr Anderson, Philip R. Tempest, Frank J. Carr, William J. Harris, Kathryn Armour
-
Patent number: 6737061Abstract: Novel humanized monoclonal antibodies, humanized antibody fragments, and derivatives thereof which specifically bind TAG-72 are provided as well as methods for their manufacture. These humanized antibodies are useful in the treatment of cancers which express TAG-72 as well as for diagnostic purposes, e.g., for in vivo imaging of tumors or cancer cells which express TAG-72.Type: GrantFiled: October 31, 2001Date of Patent: May 18, 2004Assignee: The Dow Chemical CompanyInventors: W. H. Kerr Anderson, Philip R. Tempest, Frank J. Carr, William J. Harris, Kathryn Armour
-
Patent number: 6734286Abstract: An effective anti-IL-5 recombinant antibody molecule comprising heavy and/or light chain antigen-binding residues from a donor antibody.Type: GrantFiled: May 15, 2001Date of Patent: May 11, 2004Assignee: Celltech R&D LimitedInventors: Mark William Bodmer, Diljeet Singh Athwal, John Spencer Emtage
-
Patent number: 6719971Abstract: Variant immunoglobulins, particularly humanized antibody polypeptides are provided, along with methods for their preparation and use. Consensus immunoglobulin sequences and structural models are also provided.Type: GrantFiled: November 2, 2000Date of Patent: April 13, 2004Assignee: Genentech, Inc.Inventors: Paul J. Carter, Leonard G. Presta
-
Patent number: 6716598Abstract: The invention herein provides a method for recovering a polypeptide comprising exposing a composition comprising a polypeptide to a reagent which binds to, or modifies, the polypeptide, wherein the reagent is immobilized on a solid phase; and then passing the composition through a filter bearing a charge which is opposite to the charge of the reagent in the composition, so as to remove leached reagent from the composition.Type: GrantFiled: August 27, 2001Date of Patent: April 6, 2004Assignee: Genentech, Inc.Inventors: Gregory S. Blank, Daljit S. Narindray, Gerardo A. Zapata
-
Patent number: 6716968Abstract: Apoptosis-related antigenic compounds comprising an exposed antigenic site having the amino acid sequence SEQ ID NO: 1: Glu Asp Phe Asn Leu Gly Asp Ala Leu Asp 1 5 10 or a functionally equivalent sequence comprising at least the sequence Ala Leu Asp are disclosed.Type: GrantFiled: July 27, 2001Date of Patent: April 6, 2004Assignee: Peviva ABInventors: Viveka Björklund, Bertil Björklund, Peter Björklund, Marius Nap, Frans C. S. Ramaekers, Bert Schutte